BioSpace News Archive

BioNTech inked an exclusive worldwide license and collaboration agreement with OncoC4 to develop and commercialize its investigational anti-CTLA-4 antibody ONC-392 for solid tumors.

Peter Marks described the steps the agency is taking to advance the development of gene therapies for rare disorders. This could spell good news in the near future for Sarepta Therapeutics.

With some proactive measures, you can make it more likely your stocks will remain yours in the event of a layoff.

Following recent meetings with the FDA and European Medicines Agency, Mereo Biopharma is designing a Phase III study of alvelestat to treat alpha-1-antitrypsin deficiency-associated lung disease.

Semler Scientific, Inc. reported financial results for the three months and year ended December 31, 2022.

Imunon, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 5,250 shares of common stock and restricted stock grants totaling 1,100 shares of common stock as a material inducement to the employment to two individuals hired by Imunon during the first quarter of 2023.

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2022.

DURECT Corporation announced that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.

Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced four poster presentations from preclinical studies of its LGR5-targeting CAR-T platform in colorectal cancer at the 2023 American Association for Cancer Research (AACR) Annual Meeting that will take place in Orlando, Florida on April 14-19.

Predictive Oncology Inc. (Nasdaq: POAI), Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today reported financial and operating results for the year ended December 31, 2022, and provided a corporate update.